PatentsUSA
US Court Orders Biogen to Pay Genentech $88 Million in Multiple Sclerosis Drug Royalty Dispute
A US federal court has ruled that Biogen must pay Genentech $88 million in a patent royalty dispute concerning a multiple sclerosis drug. The judgment resolves a high-stakes conflict between two biotech giants over licensing agreements and revenue sharing tied to the drug's commercial success.
Thursday, May 14, 2026